North America Non-Alcoholic Steatohepatitis Market
Historic Data:    |   Base Year: 2023   |   Forecast Period: 2024-2031
Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib, Cenicriviroc, and Others), Application (Treatment and Diagnosis), and Sales Channel (Hospital Pharmacy, Online Provider, and Retail Pharmacy)

No. of Pages: 116    |    Report Code: BMIRE00025407    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
North America Non-Alcoholic Steatohepatitis Market
Free Sample Buy Now

1. Introduction

1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. North America Non-Alcoholic Steatohepatitis Market Landscape

4.1 Market Overview
4.2 Porter's Five Forces Analysis
  • 4.2.1 Bargaining Power of Suppliers
  • 4.2.2 Bargaining Power of Buyers
  • 4.2.3 Threat of New Entrants
  • 4.2.4 Competitive Rivalry
  • 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
  • 4.3.1 Raw Material Suppliers
  • 4.3.2 Manufacturers
  • 4.3.3 Distributors/Suppliers
  • 4.3.4 End Users

5. North America Non-Alcoholic Steatohepatitis Market – Key Market Dynamics

5.1 Growth Drivers
  • 5.1.1 Increasing Initiatives for the Awareness of NASH Favors the Market Growth
5.2 Market Opportunities
  • 5.2.1 High Competition among Market Players to Manufacture the First Marketed NASH Drug Creates Global Sales Opportunity
5.3 Future Trends
  • 5.3.1 Growing Clinical Trials Involving Combination Studies of Drugs
5.4 Impact of Drivers and Restraints

6. North America Non-Alcoholic Steatohepatitis Market Regional Analysis

6.1 North America Non-Alcoholic Steatohepatitis Market Overview
6.2 North America Non-Alcoholic Steatohepatitis Market Revenue 2019-2028 (US$ Million)
6.3 North America Non-Alcoholic Steatohepatitis Market Forecast Analysis

7. North America Non-Alcoholic Steatohepatitis Market Analysis – by Product

7.1 Vitamin E and Pioglitazone
  • 7.1.1 Overview
  • 7.1.2 Vitamin E and Pioglitazone: North America Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Ocaliva
  • 7.2.1 Overview
  • 7.2.2 Ocaliva: North America Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Elafibranor
  • 7.3.1 Overview
  • 7.3.2 Elafibranor: North America Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Selonsertib
  • 7.4.1 Overview
  • 7.4.2 Selonsertib: North America Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2031 (US$ Million)
7.5 Cenicriviroc
  • 7.5.1 Overview
  • 7.5.2 Cenicriviroc: North America Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2031 (US$ Million)

8. North America Non-Alcoholic Steatohepatitis Market Analysis – by Application

8.1 Treatment
  • 8.1.1 Overview
  • 8.1.2 Treatment: North America Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)
8.2 Diagnosis
  • 8.2.1 Overview
  • 8.2.2 Diagnosis: North America Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)

9. North America Non-Alcoholic Steatohepatitis Market Analysis – by Sales Channel

9.1 Hospital Pharmacy
  • 9.1.1 Overview
  • 9.1.2 Diagnosis: North America Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)
9.2 Online Provider
  • 9.2.1 Overview
  • 9.2.2 Diagnosis: North America Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)
9.3 Retail Pharmacy
  • 9.3.1 Overview
  • 9.3.2 Diagnosis: North America Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)

10. North America Non-Alcoholic Steatohepatitis Market – North America Analysis

10.1 North America
  • 10.1.1 North America Non-Alcoholic Steatohepatitis Market Breakdown, by Key Country, 2022 and 2028 (%)
  • 10.1.1.1 North America Non-Alcoholic Steatohepatitis Market – Revenue and Forecast Analysis – by Country
  • 10.1.1.1 US: North America Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.1.1 US: North America Non-Alcoholic Steatohepatitis Market Breakdown, by Product
    • 10.1.1.1.2 US: North America Non-Alcoholic Steatohepatitis Market Breakdown, by Application
    • 10.1.1.1.3 US: North America Non-Alcoholic Steatohepatitis Market Breakdown, by Sales Channel
  • 10.1.1.2 Canada: North America Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.2.1 Canada: North America Non-Alcoholic Steatohepatitis Market Breakdown, by Product
    • 10.1.1.2.2 Canada: North America Non-Alcoholic Steatohepatitis Market Breakdown, by Application
    • 10.1.1.2.3 Canada: North America Non-Alcoholic Steatohepatitis Market Breakdown, by Sales Channel
  • 10.1.1.3 Mexico : North America Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.3.1 Mexico : North America Non-Alcoholic Steatohepatitis Market Breakdown, by Product
    • 10.1.1.3.2 Mexico : North America Non-Alcoholic Steatohepatitis Market Breakdown, by Application
    • 10.1.1.3.3 Mexico : North America Non-Alcoholic Steatohepatitis Market Breakdown, by Sales Channel

11. Competitive Landscape

11.1 Heat Map Analysis
11.2 Company Positioning and Concentration

12. North America Non-Alcoholic Steatohepatitis Market Industry Landscape

12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Cadila Pharmaceutical.
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
13.2 Intercept Pharmaceutical.
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
13.3 Novartis AG.
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
13.4 Galmed Pharmaceutical.
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
13.5 GENFIT.
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
13.6 Prometheus Laboratories.
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
  • 13.6.6 Key Developments
13.7 Siemens Healthineers AG.
  • 13.7.1 Key Facts
  • 13.7.2 Business Description
  • 13.7.3 Products and Services
  • 13.7.4 Financial Overview
  • 13.7.5 SWOT Analysis
  • 13.7.6 Key Developments
13.8 Laboratory Corporation of America Holdings.
  • 13.8.1 Key Facts
  • 13.8.2 Business Description
  • 13.8.3 Products and Services
  • 13.8.4 Financial Overview
  • 13.8.5 SWOT Analysis
  • 13.8.6 Key Developments

14. Appendix

14.1 About Business Market Insights

The List of Companies - N Market

  1. Cadila Pharmaceutical.
  2. Intercept Pharmaceutical.
  3. Novartis AG.
  4. Galmed Pharmaceutical.
  5. GENFIT.
  6. Prometheus Laboratories.
  7. Siemens Healthineers AG.
  8. Laboratory Corporation of America Holdings.             

 

 

 

   

north-america-non-alcoholic-steatohepatitis-market